Abstract: The present application relates to the field of cell immunity, and discloses an interacting protein screening platform for preparing a cell membrane. A cell membrane protein and a membrane protein encoding gene to be tested are respectively expressed in different cells; after staining, cells expressing different membrane proteins and cells expressing target proteins are co-incubated; and then interacting membrane proteins are obtained by screening, and specific sequences thereof are determined by sequencing. The screening platform provided in the present application can screen a variety of cell membrane proteins and membrane protein-based engineering cells, and has strong specificity, thereby greatly improving the efficiency of screening interacting proteins and reducing the difficulty, providing a simple and convenient tool for studying the mechanism of action of cell membrane proteins, and improving the screening throughput.

Abstract: Provided are use of a macrolide antibiotic in blocking influenza virus infection and use of the macrolide antibiotic in preparing a drug for treating or preventing influenza virus infection.

Abstract: Provided are a cell line PA/PB1 HEK293T (Teton) for screening an influenza virus polymerase assembly inhibitors and a construction method thereof. The PA/PB1 HEK293T (Teton) cell line is constructed by integrating a vector expressing PA-GlucC fusion protein and a vector expressing GlucN-PB1 fusion protein into a HEK293T (Teton) cell via a triple plasmid system of pMDLg/pRRE, pRSV-Rev and pMD2.G. The HEK293T (Teton) cell line is formed by transforming a TOP10 competent cell with a synthesized Teton-3G gene fragment ligated to a lentiviral vector FG.

Abstract: The invention provides a pharmaceutical composition and a method for treating cancer, and the composition comprises a proteasome inhibitor and a nuclear export inhibitor. The composition has synergistic effects on treating cancers, particularly a solid tumor cancer. Specifically, the proteasome inhibitor bortezomib and CRM1 inhibitor KPT330 induce apoptosis and cell cycle arrest in sensitive cells, such as HCT116 and RKO cells. Bortezomib induces the nuclear export of p53, whereas it could be effectively blocked by KPT330. CRM1 inhibitor KPT330 synergistically sensitizes CRC cells to bortezomib treatment in vitro and in vivo, through inhibiting nuclear export and restoring functions of p53. The invention also provides use of proteasome inhibitor in a solid tumor cancer. The invention provides a rationale for the use of proteasome inhibitor together with nuclear export blocker in the treatment of cancers, such as colorectal cancer.